Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/5/2019 |
| Start Date: | January 2009 |
| End Date: | December 2020 |
A Comparison of the Efficacy of Continuous Venovenous Hemofiltration Versus Continuous Venovenous Hemodialysis for Renal Replacement Therapy in Acute Kidney Injury
Acute kidney injury is often treated with the use of continuous renal replacement therapy.
Two commonly used treatments are continuous venvenous hemofiltration (CVVH)and continuous
venovenous hemodialysis (CVVHD). CVVH uses convective clearance to remove toxins and solutes
from the patients circulation, while CVVHD relies on diffusive clearance to remove these same
toxins/solutes. This study will evaluate which of these two methods is more effective at
clearing the body of waste/solutes.
We hypothesize that renal replacement therapy by either modality (hemodialysis or
hemofiltration; CVVHD or CVVH, respectively) using a modern membrane and higher blood flow
rates will be associated with similar clearances of both small and middle molecular weight
solutes. We further believe that continuous renal replacement therapy using CVVHD will be
associated with decreased clotting events and longer hemofilter survival, as well as improved
resource utilization (i.e. nursing time, alarms, etc.).
Two commonly used treatments are continuous venvenous hemofiltration (CVVH)and continuous
venovenous hemodialysis (CVVHD). CVVH uses convective clearance to remove toxins and solutes
from the patients circulation, while CVVHD relies on diffusive clearance to remove these same
toxins/solutes. This study will evaluate which of these two methods is more effective at
clearing the body of waste/solutes.
We hypothesize that renal replacement therapy by either modality (hemodialysis or
hemofiltration; CVVHD or CVVH, respectively) using a modern membrane and higher blood flow
rates will be associated with similar clearances of both small and middle molecular weight
solutes. We further believe that continuous renal replacement therapy using CVVHD will be
associated with decreased clotting events and longer hemofilter survival, as well as improved
resource utilization (i.e. nursing time, alarms, etc.).
Inclusion Criteria:
- Age 18 or older and able to sign consent (or surrogate).
- Must have been referred to the inpatient Nephrology consult service for evaluation of
AKI.
- Expected survival of at least 48 hours.
Exclusion Criteria:
- Hemoglobin < 8 g/dl
- Serum potassium ≥6.5mEq/L
- Weight > 120kg.
We found this trial at
1
site
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
